Toggle Main Menu Toggle Search

Open Access padlockePrints

Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer

Lookup NU author(s): Professor Thomas Lennard

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Ifosfamide has single agent activity in advanced breast cancer and may potentiate the activity of doxorubicin. The combination of ifosfamide 5 g/m(2) and doxorubicin 40 mg/m(2) every 3 weeks for 4 cycles was used to treat 77 patients with advanced breast cancer. Fifty three patients had not received prior chemotherapy. All patients had one or more poor prognostic features, including tumor expression of epidermal growth factor receptor in 11/12 tested. The overall response rate was 74% (95% confidence intervals 62%-83%). The median survival was 9.4 months. The principal toxicities were febrile neutropenia and ifosfamide encephalopathy each in 6% of patients. A high percentage of the projected dose intensity was administered. This is a highly active combination with acceptable toxicity in advanced breast cancer, although the long term survival remains poor. Further exploration of ifosfamide in combination chemotherapy for advanced breast cancer is warranted.


Publication metadata

Author(s): Millward M, Lind M, Gumbrell L, Robinson A, Lennard TWJ, Cantwell B

Publication type: Article

Publication status: Published

Journal: Breast Cancer Research and Treatment

Year: 1994

Volume: 29

Issue: 3

Pages: 271-277

Print publication date: 01/01/1994

ISSN (print): 0167-6806

ISSN (electronic): 1573-7217

URL: http://dx.doi.org/10.1007/BF00666481

DOI: 10.1007/BF00666481


Altmetrics

Altmetrics provided by Altmetric


Share